Merck, the FDA and Arcoxia (etoricoxib)
Seems Merck is in the news a lot recently. Now, the FDA has sent an Approvable letter to them for Arcoxia. This means that although the FDA thinks the compound could be approved, they need mor information before they can make that determination.
PharmaLive: Merck Responds to FDA-Issued Approvable Letters for Arcoxia (etoricoxib)
Results mixed on Merck’s new painkiller - Yahoo! News
Results of this study were published in The Lancet (DOI:10.1016/S0140-6736(06)69666-9) recently and many experts have reservations. While I think there is indeed a need for pain relief for those suffering from arthritis, the similarity to Vioxx needs to be taken into account and hopefully, the FDA will indeed insist that the proper trials are carried out and no shortcuts are taken.
Currently Celebrex from Pfizer is the only Cox-2 inhibitor still on the market.
Technorati Tags: Arcoxia, etoricoxib, Merck
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
